TOPLINE: Patients with type 2 diabetes (T2D) who received glucagon-like peptide 1 (GLP-1) receptor agonists had a significantly lower risk of developing local or systemic complications — even if they developed acute pancreatitis — and showed more than a 50% reduction in risk for all-cause mortality than those who did not receive these medications. METHODOLOGY: … Read more
TOPLINE: Almost one fifth of patients hospitalized for necrotizing pancreatitis (NP) will be readmitted within 30 days, with biliary and idiopathic pancreatitis carrying higher risk than alcohol-induced disease, according to a new study. METHODOLOGY: NP is associated with a significant healthcare burden, including hospital admission, but few studies have evaluated readmission rates of NP. Researchers … Read more
We know now that glucagon-like peptide 1 (GLP-1) drugs for obesity bring with them a whole host of other potential benefits, as well as a handful of side effects. But new research has brought a sharper focus on both the pros and the cons of these medications, and with that comes new challenges and opportunities … Read more
Norovirus cases continue to rise in the United States this winter, at levels higher than the same time period in previous years, according to the latest data from the Centers for Disease Control and Prevention (CDC). Current data from the CDC’s NoroSTAT monitoring system show 495 reported outbreaks during the period from August 1, 2024, … Read more